Clinical Trial Update: The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients

View source ↗

Summary

This clinical trial update discusses the potential of using quantitative T cell receptor repertoire analysis to predict response to anti-PD-L1 therapy in non-sm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PD-L1 inhibitors (anti-PD-L1 therapy)

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: Non-Small Cell Lung Cancer | Status: UNKNOWN